Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

被引：9
|
作者：
Ansell, Stephen M. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
LANCET HAEMATOLOGY | 2019年 / 6卷 / 01期
关键词：
CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; NIVOLUMAB; PEMBROLIZUMAB; MULTICOHORT; BLOCKADE; FAILURE;
D O I：
10.1016/S2352-3026(18)30210-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E2 / E3
页数：2
相关论文
共 50 条
  • [1] Immune checkpoint inhibition in classical hodgkin lymphoma
    Pezeshki, Parmida Sadat
    Eskian, Mahsa
    Hamblin, Michael R.
    Rezaei, Nima
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 1003 - 1016
  • [2] The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
    Meti, Nicholas
    Esfahani, Khashayar
    Johnson, Nathalie A.
    CANCERS, 2018, 10 (06)
  • [3] MD Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma.
    Nair, Ranjit
    Pinnix, Chelsea Camille
    Gunther, Jillian Rebecca
    Strati, Paolo
    Westin, Jason
    Fayad, Luis
    Hagemeister, Fredrick B.
    Iyer, Swaminathan Padmanabhan
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Steiner, Raphael
    Dabaja, Bouthaina Shbib
    Fang, Penny
    Flowers, Christopher
    Noorani, Mansoor
    Feng, Lei
    Neelapu, Sattva Swarup
    Ahmed, Sairah
    Lee, Hun Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] DISTURBED ANTIGEN PRESENTATION IN CLASSICAL HODGKIN LYMPHOMA; IMPLICATIONS FOR IMMUNE CHECKPOINT INHIBITOR THERAPY?
    Nijland, M.
    Visser, L.
    Veenstra, R.
    Kushekhar, K.
    van Imhoff, G.
    van den Berg, A.
    Diepstra, A.
    HAEMATOLOGICA, 2016, 101 : 30 - 30
  • [5] Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition
    De Re, Valli
    Caggiari, Laura
    Repetto, Ombretta
    Mussolin, Lara
    Mascarin, Maurizio
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [6] Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma
    Nakhoda, Shazia
    Rizwan, Farsha
    Vistarop, Aldana
    Nejati, Reza
    CANCERS, 2022, 14 (12)
  • [7] Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
    Carella, A. M.
    Corradini, P.
    Mussetti, A.
    Ricardi, U.
    Vitolo, U.
    Viviani, S.
    ANNALS OF HEMATOLOGY, 2018, 97 (08) : 1301 - 1315
  • [8] Discontinuation of immune checkpoint inhibitors in patients with relapsed and refractory classical Hodgkin lymphoma
    Fedorova, L.
    Lepik, K.
    Kotselyabina, P.
    Kondakova, E.
    Popova, M.
    Borzenkova, E.
    Moiseev, I.
    Mikhailova, N.
    Kulagin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1435 - S1436
  • [9] Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
    A. M. Carella
    P. Corradini
    A. Mussetti
    U. Ricardi
    U. Vitolo
    S. Viviani
    Annals of Hematology, 2018, 97 : 1301 - 1315
  • [10] Immune Checkpoint Inhibition in Hodgkin Lymphoma
    Moy, Ryan H.
    Younes, Anas
    HEMASPHERE, 2018, 2 (01):
12345